

1 Omega-3 Index is Directly Associated with a Healthy Red Blood Cell Distribution Width

2 Michael I. McBurney¹⁻³, Nathan L. Tintle^{1,4}, and William S. Harris^{1,5}

3 ¹Fatty Acid Research Institute, Sioux Falls, SD 57106, USA (MIM, NLT, WSH); ²Department of
4 Human Health and Nutritional Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada
5 (MIM), ³Division of Biochemical and Molecular Biology, Friedman School of Nutrition Science
6 and Policy, Tufts University, Boston, MA 02111, USA (MIM); ⁴Department of Population Health
7 Nursing Science, College of Nursing, University of Illinois – Chicago, Chicago, IL 60612,
8 USA(NLT); ⁵Sanford School of Medicine, University of South Dakota, Sioux Falls, SD 57105, USA
9 (WSH).

10

11 **Authors' last names:** McBurney, Tintle, Harris

12 **Corresponding author:** M.I. McBurney, Department of Human Health & Nutritional Sciences,
13 University of Guelph, Guelph, ON N1G 2W1, Canada. E-mail: mim@faresinst.com

14 **Reprint requests:** W.S. Harris, Fatty Acid Research Institute, Sioux Falls, SD 57106, USA. E-mail:
15 wsh@faresinst.com

16 **Sources of Support:** This work was supported by the Fatty Acid Research Institute (FARI). FARI is
17 a non-profit foundation bringing together nutrition scientists and biostatistical experts to
18 accelerate discovery of the relationships between fatty acids, especially omega-3 fatty acids,
19 and health. Pending application and approval, data described in the manuscript, code book, and
20 analytic code will be made available upon request to the Fatty Acid Research Institute
21 (<https://www.faresinst.org/>).

22 **Abbreviations:** BMI, body mass index; CRP, high-sensitivity C-reactive protein; CV, coefficient of
23 variation; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Hb, hemoglobin; MCV,

24 mean corpuscular volume; O3I, omega-3 index; RBC, red blood cells. RDW, red blood cell

25 distribution width; SD, standard deviation.

26

27 **Summary**

28 Low red blood cell (RBC) membrane content of EPA and DHA, i.e., the omega-3 index (O3I),
29 and elevated RBC distribution width (RDW) are risk factors for all-cause mortality. O3I and RDW
30 are related with membrane fluidity and deformability. Our objective was to determine if there
31 is a relationship between O3I and RDW in healthy adults. Subjects without inflammation or
32 anemia, and with values for O3I, RDW, high-sensitivity C-reactive protein (CRP), body mass
33 index (BMI), age and sex were identified (n=25,485) from a clinical laboratory dataset of
34 >45,000 individuals. RDW was inversely associated with O3I in both sexes before and after
35 (both $p < 0.00001$) adjusting models for sex, age, BMI and CRP. Stratification by sex revealed a
36 sex-O3I interaction with the RDW-O3I slope ($p < 0.00066$) being especially steep in females with
37 O3I $\leq 5.6\%$. In healthy adults of both sexes, the data suggested that an O3I of $> 5.6\%$ may help
38 maintain normal RBC structural and functional integrity.

39

40 **Keywords:** hematology, red blood cells, omega-3 index, eicosapentaenoic acid,

41 docosahexaenoic acid

42

43

44 **1. Introduction**

45 Mean red blood cell (RBC) corpuscular volume (MCV) and reticulocyte count were the
46 principal metrics traditionally used to identify anemic disorders until the advent of automated
47 blood cell analyzers that could routinely measure the types and distribution of blood cells.
48 Among these metrics is the RBC distribution width (RDW) [1] which reflects RBC size
49 heterogeneity. High RDW values are associated with decreased deformability [2] and RDW is
50 used to diagnose sickle cell [3] and nutritional anemias (iron, folic acid and vitamin B12) [1,4,5].
51 In recent years, RDW has been found to be a predictor of multiple adverse health outcomes
52 unrelated to anemia, including increased risk for death from cardiovascular disease [6–12],
53 SARS-CoV-2 [13–15], sepsis [16,17], lung disease [18], and cancer [19,20].

54 Like all cell membranes, RBC membranes are a complex lipid bilayer [21]. Fatty acids
55 esterified in phospholipids contribute to the structural integrity and function of cell
56 membranes. In particular, the membrane content of omega-3 fatty acids, EPA and DHA, the
57 sum of which is called the omega-3 index (O3I) [22], increases with omega-3 fatty acid intake
58 [23,24] and affects cell deformability [25–28]. The O3I is a stable biomarker of long term EPA
59 and DHA intake [24,29]. Since both a low O3I [30] and an elevated RDW [7,31,32] are known to
60 be associated with risk for earlier all-cause mortality (**Supplemental Table 1**), the aim of this
61 cross-sectional analysis was to determine if there was an inverse relationship between the O3I
62 and RDW in healthy adults without evidence of inflammation or tissue injury. If there was, then
63 the former may play a role in maintaining a healthy distribution of RBC sizes in adults.

64 Furthermore, such a relationship could support the identification of a target or healthy O3I. By
65 establishing a nutrient: structure-function relationship in healthy individuals, these data could

66 [be used as the basis for establishing a Dietary Reference Intake \(DRI\) for the long-chain omega-](#)
67 [3 fatty acids, i.e., EPA+DHA.](#)

68

69 **2. Patients and Methods**

70 This was a cross-sectional analysis of data from blood samples submitted for testing to
71 Health Diagnostic Laboratory, Inc (HDL, Inc., Richmond VA) as part of routine clinical
72 assessment between 2011-2012. Data on RBC structural characteristics, i.e., MCV and RDW,
73 along with hemoglobin (Hb), high-sensitivity C-reactive protein (CRP), [arachidonic acid \(AA\)](#),
74 [EPA, DHA](#), and O3I were extracted from 45,715 adults (≥ 18 years) without any linked patient
75 identifiers except age, sex and BMI (**Supplemental Table 2**). Next, 598 individuals with [extreme](#)
76 O3I values ([i.e., <2.15](#) and [>11.5%, the upper and lower 0.5 percentiles of the cohort](#)), were
77 excluded ($n=45,257$). Since inflammation affects erythropoiesis, modulates RBC life span, and
78 increases RDW [33], 14,329 individuals with chronic inflammation (CRP $>3\text{mg/L}$) [34–38] were
79 excluded. Similarly, anemia also increases RDW [1,39], and so individuals with MCV $>100\text{ fL}$ and
80 low Hb (Hb $<13\text{ g/dL}$ for men and Hb $<12\text{ g/dL}$ for women [40] were also excluded (**Figure 1**).

81 This resulted in a final, analytical dataset of 25,485 individuals (49.7% female) without
82 laboratory evidence of anemia or active infection, tissue injury, or inflammation (**Table 1**).

83 *2.1 Laboratory methods*

84 Blood samples were drawn after an overnight fast and shipped with cold packs to HDL, Inc.
85 for analysis with a Beckman-Coulter DxH 800 hematology analyzer (Brea, CA, USA). Samples
86 were prepared at each clinical site according to standardized instructions as previously
87 described [41]. RDW is the SD of the RBC volume divided by the MCV multiplied by 100 [39].

88 For fatty acid analysis, RBCs were separated from plasma by centrifugation and analyzed using
89 gas chromatography as previously described [42]. The University of South Dakota Institutional
90 Review Board reviewed and approved the analysis of deidentified HLD, Inc. laboratory data
91 (IRB-21-147).

92 *2.2 Statistical methods*

93 Sample characteristics were summarized using standard statistical methods (e.g., means,
94 SDs, correlations) with t-tests or adjusted linear models used to compare characteristics of male
95 and female participants above and below O3I values that were ultimately identified as primary
96 cut points in the RDW-O3I curves (see below). Splines were fit using 3rd degree polynomials
97 with knots at each decile in R (version 3.6.2; splines package). Unadjusted models used a linear
98 model to predict RDW values by splines of O3I. Adjusted models accounted for sex, age, BMI
99 and CRP values in the linear models accounting for potential non-linear relationships using
100 splines.

101 In order to identify significant changes in the shape of the RDW-O3I relationship, we used a
102 “sliding O3I window” approach. The width of each window was three O3I percentage points
103 (e.g., 3% to 6%). By moving the window up by 0.1% increments and repeatedly testing for
104 significant differences between the mean RDW in the lower vs. the upper half of the window,
105 we sought to discover O3I cut points where the RDW-O3I relationship appeared to flatten.
106 These would be O3I values above which the “effect” of an increase in O3I on RDW had little
107 impact. We began with a window midpoint of O3I =2.6%, and we used adjusted linear models in
108 R to test for upper vs lower half differences. We identified the first window which did not have
109 a statistically significant difference in upper and lower mean RDW values. The midpoint of this

110 window was chosen as the O3I cut point to be used in further analysis. To evaluate the
111 potential moderating effect of sex on the O3I relationship with RDW, MCV, Hb, CRP, BMI and
112 age, we inserted an interaction term into the relevant, adjusted model. Pearson correlations
113 were used to assess strength and direction of linear association between covariates and RDW.
114 Statistical significance was set to 0.05 for all analyses and 95% confidence bands are provided
115 where appropriate.

116 3. Results

117 The final dataset included 25,485 individuals (**Figure 1**) without acute inflammation or
118 anemia. Mean BMI, O3I, MCV, Hb, and CRP values differed significantly between males and
119 females in adjusted models (**Table 1**). RDW was significantly ($p < 0.00001$) and inversely
120 associated with O3I in unadjusted (**Figure 2A**) and adjusted models ($p < 0.00001$) (**Figure 2B**).

121 Independently, EPA and DHA had similar ‘hockey stick’ RDW-fatty acid relationships with the
122 bases of the curves being ~3% and ~7.3%, respectively (**Supplemental Figure 2**). RDW was not
123 significantly related with AA (**Supplemental Figure 2**, $r = 0.06$). Pearson correlations (r) with RDW
124 were $r = 0.21$ (age), $r = 0.11$ (CRP), $r = 0.14$ (BMI), $r = -0.25$ (MCV), and $r = -0.12$ (Hb). The O3I cut
125 point determined in the sliding window analysis, i.e. when the lower and upper half of an “O3I
126 sliding window” yielded mean RDW values that did not significantly differ, was 5.6% (**Figure 2B**).
127 That is, below an O3I of 5.6%, the curve was clearly steeper than it was above 5.6%. Because of
128 significant sex differences in RDW and O3I in the adjusted model (**Table 1**), and because of the
129 clear differences in the shapes of the RDW-O3I relationship between men and women (**Figure**
130 **2**), we stratified by sex and by O3I ($\leq 5.6\%$ vs $> 5.6\%$) (**Table 2**). Within sex comparisons found
131 significant differences between individuals with O3I $\leq 5.6\%$ vs. $> 5.6\%$ for all variables in the

132 adjusted model for females and males (**Table 2**). We observed a significant sex by O3I
133 interaction in the adjusted model for RDW and BMI for both sexes with the difference in RDW
134 below 5.6% being larger in females than males. Across all O3I concentrations, RDW continued
135 to decrease with increasing O3I in females whereas there was a plateauing in males, and even a
136 modest increase in RDW as O3I exceeded 8% (Figure 3).

137

138 4. Discussion and Conclusions

139 RBCs are by far the most common cell in the body (83%), and as such, they have recently
140 been viewed as a separate organ deeply involved with homeostasis [43]. Their primary role is to
141 transport oxygen and carbon dioxide, and to accomplish this RBCs must pass through capillaries
142 whose diameter is half of their own [44]. Thus, RBCs must be highly flexible and able to
143 withstand high-shear stress. Here, we report an inverse relationship between the percentage of
144 omega-3 fatty acids in RBC membranes and the distribution of RBC sizes in a generally healthy
145 (i.e., not anemic and without inflammation) cohort (**Figure 2**), as well as an interaction with sex
146 (**Figure 3**). In both males and females, RDW was observed to be increasing with decreasing O3I
147 below 5.6% (Figure 2; Table 2). The direction of the O3I-RDW relationship changed in males
148 with O3I >~8% but the increase in RDW is unlikely to have clinical significance.

149 Changes in saturated and unsaturated fatty acid composition in cell membranes affect
150 membrane fluidity [45–47] and deformability [28,48]. EPA and DHA have specific biophysical
151 properties that affect the properties of membranes enriched in them [49]. Among these
152 properties are fluidity, deformability, and susceptibility to aggregation of RBCs [26,28].
153 Increases in membrane DHA (a highly flexible molecule) influence the flexibility and structural

154 integrity, i.e. lipid-protein interactions, of RBC membranes [50]. Increasing EPA intake alone or
155 EPA+DHA together increases RBC membrane fluidity [48] and RBC deformability [25–27,51].
156 RBC deformability is affected by membrane lipid composition and lipid-protein interactions, and
157 reduced deformability is a characteristic of aged RBCs [52]. Since an elevated RDW is likewise
158 associated with decreased RBC membrane flexibility [2], one possible explanation for our
159 findings is that a reduced EPA+DHA content of RBC membranes is causing the elevation in RDW.

160 An elevated RDW can also be caused by disordered erythropoiesis and/or RBC clearance
161 [53]. A delay in clearance allows smaller RBCs to continue circulating, increasing the average
162 age (lifespan) of RBC, and contributes to increased RDW [2]. Oxidative stress is a characteristic
163 of aging, malnutrition, inflammation, and the pathogenesis of chronic disease [54]. Oxidative
164 stress changes cytoskeletal arrangement and contributes to lipid asymmetry, causing
165 erythrocytes lose flexibility and RDW to increase [55]. A systematic review and meta-analysis of
166 39 clinical trials (2,875 participants) found omega-3 supplementation improved antioxidant
167 stability by significantly increasing serum total antioxidant capacity and decreasing serum
168 glutathione peroxidase and malondialdehyde concentrations [56]. This represents another
169 means by which omega-3 fatty acids could improve the RDW.

170 Alternatively, there may be a connection between omega-3, inflammation and the RDW.
171 Inflammation marked by elevated CRP, interleukin-6, etc. can suppress RBC maturation in bone
172 marrow, and larger immature RBCs, i.e. reticulocytes, enter the circulation and increase the
173 RDW [16]. This relationship between RDW and inflammation may partially explain the
174 relationship of higher RDW with risk of cardiovascular disease and mortality
175 [10,11,14,30,32,57]. Similarly, lower omega-3 fatty acid levels are associated with a heightened

176 inflammatory state [58–60], and omega-3 supplementation lowers inflammatory mediators
177 [61]. Thus, a possible explanation of our findings may be that higher omega-3 fatty acid levels
178 (O3I >5.6%) lower inflammatory markers which thereby lowers the RDW. Because it has been
179 recommended that a DRI be established for EPA+DHA [62–65], the RDW-O3I analysis was
180 purposefully constrained to healthy individuals with an objective of establishing a nutrient
181 (EPA+DHA) structure-function (RDW) relationship. When the 14,239 individuals with
182 inflammation (CRP >3 mg/L) were also included in the adjusted and unadjusted models, a
183 similar inverse RDW-O3I relationship was determined (Supplemental Figure 2).

184 Because of its cross-sectional nature, we cannot draw causal inferences from these data.
185 However, there is evidence that raising RBC membrane omega-3 content can improve RDW. In
186 patients with sickle cell disease, RBC rheological disturbances, hemolysis, and abnormalities of
187 membrane fatty acids, have been ameliorated by omega-3 fatty acid treatment [66,67].
188 Supplementation with both EPA alone or EPA+DHA lowered RDW values in patients with
189 coronary heart disease [51,68] and with abdominal aortic aneurysm [69]. In the latter study,
190 supplementation increased O3I from ~4.5% to 8% and decreased RDW from 14.8% to 13.8%.
191 So, one of the mechanisms underlying the health benefits of EPA and DHA could be via an
192 improved RDW.

193 The primary strength of this study was its large sample size which enabled us to explore
194 RDW and O3I relationships in healthy individuals (males and females separately) free of
195 laboratory signs of anemia or inflammation, i.e., a population suitable for the establishment of
196 a DRI. The most obvious limitations of this study, besides its cross-sectional nature, was the lack
197 of information on confounding metabolic events, dietary behaviors, medications, other medical

198 conditions and/or physical activities that might have also been associated with O3I and with
199 RDW. Another potential limitation is that these data were drawn from a clinical laboratory
200 database, not a formal national survey, so the representativeness of these patients to healthy
201 US adults is not clear. However, previous studies in this specific cohort found that standard risk
202 biomarkers (cholesterol, glucose, etc.) generally reflected those of typical adults living in the
203 United States examined in Nutrition And Health Examination Surveys (NHANES) [70]. Also, O3I
204 values were similar to those from a representative US sample [71], and RDW, MCV, and Hb
205 were within normal ranges [7,72,73]. These considerations suggest this cohort was generally
206 representative of the US population. The mean serum EPA+DHA concentration for adults 20+
207 years from NHANES was 2% [71] which is equivalent to an O3I of about 4.8%. Hence, roughly
208 half of Americans have an O3I <5%, i.e., the range where higher RDW may be more common.

209 In conclusion, low O3I levels ($\leq 5.6\%$) were associated with a potentially unhealthy
210 distribution of RBC cell sizes. This suggests a role for EPA+DHA in maintaining RBC structure in
211 healthy individuals. We propose that achieving an O3I $>5.6\%$ could help maintain a normal RBC
212 size distribution. Our finding complements evidence that a higher O3I is linearly and inversely
213 associated with risk for death from any cause [30], with values of $>8\%$ characterizing the lowest
214 risk population [74]. Numerous researchers have called for the establishment of Dietary
215 Reference Intake (DRI) for EPA+DHA [63–65]. To that end, our observations that maintaining an
216 RBC EPA+DHA percentage above 5.6% may help maintain a normal RDW, could provide the
217 scientific basis for a DRI.

218

219 **Disclosures:** M.I. McBurney serves on the Board of Directors of the American Society for
220 Nutrition and has or has held consulting agreements in the past 3 years with Council for
221 Responsible Nutrition; Church & Dwight; DSM Nutritional Products; International Life Sciences
222 Institute, North America; McCormick; OmegaQuant Analytics; PepsiCo; and VitaMe
223 Technologies. W.S. Harris holds an interest in OmegaQuant Analytics, a lab that offers omega-3
224 blood testing; and is a member of the RB Schiff Science and Innovation Advisory Board. N.L.
225 Tintle has no conflicts to disclose.

226 **Funding:** This work was supported by the Fatty Acid Research Institute (FARI). FARI is a non-
227 profit foundation bringing together nutrition scientists and biostatistical experts to accelerate
228 discovery of the relationships between fatty acids, especially omega-3 fatty acids, and health.

229 **CReditT authorship contribution statement:** **M.I. McBurney:** Conceptualization & analytical
230 design, Writing - original draft, Writing - review & editing. **W.S. Harris:** Conceptualization &
231 analytical design, Funding - acquisition, Writing- review & editing. **N.L. Tintle:** Formal analysis,
232 Writing - review & editing.

233 **Acknowledgements:** The authors wish to thank Dr. Patrick Moriarty, Department of Internal
234 Medicine, Kansas University Medical Center, Kansas City, KS for the initial suggestion to explore
235 the relationship between omega-3 status and RDW. We also are indebted to Steven Varvel, PhD
236 for his help in acquiring and collating the dataset used in this study.

237

238 **References**

- 239 [1] J.D. Bessman, P.R. Gilmer, F.H. Gardner, Improved Classification of Anemias by MCV and
240 RDW, *Am J Clin Pathol.* 80 (1983) 322–326. <https://doi.org/10.1093/ajcp/80.3.322>.
- 241 [2] K.V. Patel, J.G. Mohanty, B. Kanapuru, C. Hesdorffer, W.B. Ershler, J.M. Rifkind, Association
242 of the Red Cell Distribution Width with Red Blood Cell Deformability, in: W.J. Welch, F.
243 Palm, D.F. Bruley, D.K. Harrison (Eds.), *Oxygen Transport to Tissue XXXIV*, Springer New
244 York, New York, NY, 2013: pp. 211–216. https://doi.org/10.1007/978-1-4614-4989-8_29.
- 245 [3] D.J. Schweiger, Red cell distribution width in sickle cell anemia, *Am J Med Technol.* 47
246 (1981) 231–233.
- 247 [4] R.O. Wallerstein, Laboratory Evaluation of Anemia, *West J Medicine.* 146 (1987) 443–451.
- 248 [5] W.G. Thompson, T. Meola, M. Lipkin, M.L. Freedman, Red Cell Distribution Width, Mean
249 Corpuscular Volume, and Transferrin Saturation in the Diagnosis of Iron Deficiency, *JAMA*
250 *Intern. Med.* 148 (1988) 2128–2130.
- 251 [6] M. Tonelli, F. Sacks, M. Arnold, L. Moye, B. Davis, M. Pfeffer, Relation between Red Blood
252 Cell Distribution Width and Cardiovascular Event Rate in People with Coronary Disease,
253 *Circulation.* 117 (2008) 163–168. <https://doi.org/10.1161/CIRCULATIONAHA.107.727545>.
- 254 [7] S.K. Zalawadiya, V. Veeranna, S.S. Panaich, L. Afonso, J.K. Ghali, Gender and Ethnic
255 Differences in Red Cell Distribution Width and Its Association With Mortality Among Low
256 Risk Healthy United State Adults, *The American Journal of Cardiology.* 109 (2012) 1664–
257 1670. <https://doi.org/10.1016/j.amjcard.2012.01.396>.
- 258 [8] B.F. Makhoul, A. Khourieh, M. Kaplan, F. Bahouth, D. Aronson, Z.S. Azzam, Relation
259 between changes in red cell distribution width and clinical outcomes in acute

- 260 decompensated heart failure, *Int J Cardiol.* 167 (2013) 1412–1416.
- 261 <https://doi.org/10.1016/j.ijcard.2012.04.065>.
- 262 [9] N. Li, H. Zhou, Q. Tang, Red Blood Cell Distribution Width: A Novel Predictive Indicator for
- 263 Cardiovascular and Cerebrovascular Diseases, *Disease Markers.* 2017 (2017) 1–23.
- 264 <https://doi.org/10.1155/2017/7089493>.
- 265 [10] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution
- 266 width and risk of cardiovascular mortality: Insights from National Health and Nutrition
- 267 Examination Survey (NHANES)-III, *Int. J. Cardiol.* 232 (2017) 105–110.
- 268 <https://doi.org/10.1016/j.ijcard.2017.01.045>.
- 269 [11] S. Huang, Q. Zhou, N. Guo, Z. Zhang, L. Luo, Y. Luo, Z. Qin, L. Ge, Association between red
- 270 blood cell distribution width and in-hospital mortality in acute myocardial infarction,
- 271 *Medicine.* 100 (2021) e25404. <https://doi.org/10.1097/MD.00000000000025404>.
- 272 [12] D. Lazzeroni, L. Moderato, P.L. Marazzi, C. Pellegrino, E. Musiari, P. Castiglioni, U.
- 273 Camaiora, M. Bini, S. Geroldi, L. Brambilla, V. Brambilla, P. Coruzzi, Red blood cell
- 274 distribution width as a novel prognostic marker after myocardial revascularization or
- 275 cardiac valve surgery, *Sci Rep.* 11 (2021) 7889. [https://doi.org/10.1038/s41598-021-](https://doi.org/10.1038/s41598-021-87075-4)
- 276 87075-4.
- 277 [13] B.H. Foy, J.C.T. Carlson, E. Reinertsen, R. Padros I. Valls, R. Pallares Lopez, E. Palanques-
- 278 Tost, C. Mow, M.B. Westover, A.D. Aguirre, J.M. Higgins, Association of Red Blood Cell
- 279 Distribution Width with Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection,
- 280 *JAMA Network Open.* 3 (2020) e2022058.
- 281 <https://doi.org/10.1001/jamanetworkopen.2020.22058>.

- 282 [14] J.L. Rapp, D. Tremblay, N. Alpert, W. Lieberman-Cribbin, J. Mascarenhas, E. Taioli, S.
283 Ghaffari, Red cell distribution width is associated with mortality in non-anemic patients
284 with COVID-19, *J Med Virol.* (2021) jmv.27011. <https://doi.org/10.1002/jmv.27011>.
- 285 [15] Z. Wang, Y.-W. Lin, X. Wei, F. Li, X.-L. Liao, H. Yuan, D. Huang, T. Qin, H. Geng, S. Wang,
286 Predictive Value of Prognostic Nutritional Index on COVID-19 Severity, *Front. Nutr.* 7
287 (2021) 582736. <https://doi.org/10.3389/fnut.2020.582736>.
- 288 [16] E. Dalbaşı, Ö.L. Akgül, Are average platelet volume, red cell distribution width and platelet
289 distribution width guiding markers for acute appendicitis treatment options?, *Int J Clin*
290 *Pract.* (2021). <https://doi.org/10.1111/ijcp.14232>.
- 291 [17] Y. Li, Y. She, L. Fu, R. Zhou, W. Xiang, L. Luo, Association Between Red Cell Distribution
292 Width and Hospital Mortality in Patients with Sepsis, *J Int Med Res.* 49 (2021)
293 030006052110042. <https://doi.org/10.1177/03000605211004221>.
- 294 [18] H. Go, H. Ohto, K.E. Nollet, K. Sato, H. Ichikawa, Y. Kume, Y. Kanai, H. Maeda, N.
295 Kashiwabara, K. Ogasawara, M. Sato, K. Hashimoto, M. Hosoya, Red cell distribution width
296 as a predictor for bronchopulmonary dysplasia in premature infants, *Sci Rep.* 11 (2021)
297 7221. <https://doi.org/10.1038/s41598-021-86752-8>.
- 298 [19] Y. Koma, A. Onishi, H. Matsuoka, N. Oda, N. Yokota, Y. Matsumoto, M. Koyama, N. Okada,
299 N. Nakashima, D. Masuya, H. Yoshimatsu, Y. Suzuki, Increased Red Blood Cell Distribution
300 Width Associates with Cancer Stage and Prognosis in Patients with Lung Cancer, *PLoS ONE.*
301 8 (2013) e80240. <https://doi.org/10.1371/journal.pone.0080240>.
- 302 [20] Q. Chen, R. Mao, J. Zhao, X. Bi, Z. Li, Z. Huang, Y. Zhang, J. Zhou, H. Zhao, J. Cai,
303 Nomograms incorporating preoperative RDW level for the prediction of postoperative

- 304 complications and survival in colorectal liver metastases after resection, *Ann Palliat Med.*
305 10 (2021) 4143–4158. <https://doi.org/10.21037/apm-20-2418>.
- 306 [21] T. Dingjan, A.H. Futerman, The fine-tuning of cell membrane lipid bilayers accentuates
307 their compositional complexity, *BioEssays.* (2021) 1–15.
308 <https://doi.org/10.1002/bies.202100021>.
- 309 [22] W.S. Harris, C. von Schacky, The Omega-3 Index: a new risk factor for death from coronary
310 heart disease?, *Prev. Med.* 39 (2004) 212–220.
311 <https://doi.org/10.1016/j.ypmed.2004.02.030>.
- 312 [23] H.M. Vidgren, J.J. Agren, U. Schwab, T. Rissanen, O. Hänninen, M.I. Uusitupa,
313 Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes
314 and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-
315 rich oil among healthy young men, *Lipids.* 32 (1997) 697–705.
- 316 [24] M.R. Flock, A.C. Skulas-Ray, W.S. Harris, T.D. Etherton, J.A. Fleming, P.M. Kris-Etherton,
317 Determinants of erythrocyte omega-3 fatty acid content in response to fish oil
318 supplementation: A dose–response randomized controlled trial, *J. Am. Heart Assoc.* 2
319 (2013) e000513. <https://doi.org/10.1161/JAHA.113.000513>.
- 320 [25] T. Terano, A. Hirai, T. Hamazaki, S. Kobayashi, T. Fujita, Y. Tamura, A. Kumagai, Effect of
321 oral administration of highly purified eicosapentaenoic acid on platelet function, blood
322 viscosity and red cell deformability in healthy human subjects, *Atherosclerosis.* 46 (1983)
323 321–331.
- 324 [26] I.J. Cartwright, A.G. Pockley, J.H. Galloway, M. Greaves, F.E. Preston, The effects of dietary
325 omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids,

- 326 erythrocyte deformability and blood viscosity in healthy volunteers, *Atherosclerosis*. 55
327 (1985) 267–281.
- 328 [27] R. Bach, U. Schmidt, F. Jung, H. Kiesewetter, B. Hennen, E. Wenzel, H. Schieffer, L. Bette, S.
329 Heyden, Effects of Fish Oil Capsules in Two Dosages on Blood Pressure, Platelet Functions,
330 Haemorheological and Clinical Chemistry Parameters in Apparently Healthy Subjects, *Ann*
331 *Nutr Metab*. 33 (1989) 359–367. <https://doi.org/10.1159/000177559>.
- 332 [28] E. Hessel, J.J. Agren, M. Paulitschke, O. Hanninen, A. Hanninen, D. Lerche, Freshwater fish
333 diet affects lipid composition, deformability and aggregation properties of erythrocytes,
334 *Atherosclerosis*. 82 (1990) 37–42.
- 335 [29] R.E. Walker, K.H. Jackson, N.L. Tintle, G.C. Shearer, A. Bernasconi, S. Masson, R. Latini, B.
336 Heydari, R.Y. Kwong, M. Flock, P.M. Kris-Etherton, A. Hedengran, R.M. Carney, A. Skulas-
337 Ray, S.S. Gidding, A. Dewell, C.D. Gardner, S.M. Grenon, B. Sarter, J.W. Newman, T.L.
338 Pedersen, M.K. Larson, W.S. Harris, Predicting the effects of supplemental EPA and DHA
339 on the omega-3 index, *Am. J. Clin. Nutr*. 110 (2019) 1034–1040.
340 <https://doi.org/10.1093/ajcn/nqz161>.
- 341 [30] W.S. Harris, N.L. Tintle, F. Imamura, F. Qian, A.V. Ardisson Korat, M. Marklund, L. Djoussé,
342 J.K. Bassett, P.-H. Carmichael, Y.-Y. Chen, Y. Hirakawa, L.K. Kupers, M. Lankinen, R.A.
343 Murphy, C. Samieri, M.K. Senn, P. Shi, J.K. Virtanen, I.A. Brouwer, K.-L. Chien, G.
344 Eiriksdottir, N.G. Forouhi, J.M. Geleijnse, G.G. Giles, V. Gudnason, C. Helmer, A. Hodge, R.
345 Jackson, K.-T. Khaw, M. Laakso, H. Lai, D. Laurin, J. Lindsay, R. Micha, J. Mursu, T.
346 Ninomiya, W. Post, B.M. Psaty, U. Riserus, J.G. Robinson, A.H. Shadyab, L. Snetelaar, A.
347 Sala-Vila, Y. Sun, L.M. Steffen, M.Y. Tsai, N.J. Wareham, A.C. Wood, J.H.Y. Wu, F. Hu, Q.

- 348 Sun, D.S. Siscovick, R.N. Lemaitre, D. Mozaffarian, F. The Fatty Acids and Outcomes
349 Research Consortium, Blood n-3 fatty acid levels and total and cause-specific mortality
350 from 17 prospective studies, *Nature Commun.* 12 (2021) 1–9.
351 <https://doi.org/10.1038/s41467-021-22370-2>.
- 352 [31] C. Fava, F. Cattazzo, Z.-D. Hu, G. Lippi, M. Montagnana, The role of red blood cell
353 distribution width (RDW) in cardiovascular risk assessment: useful or hype?, *Ann. Transl.*
354 *Med.* 7 (2019) 581–581. <https://doi.org/10.21037/atm.2019.09.58>.
- 355 [32] P.M. Moriarty, P.G. Steg, L.K. Gorby, A.M. Zeiher, H.D. White, T. Sourdille, M.T. Roe, M.J.
356 Louie, J.W. Jukema, R.A. Harrington, S.G. Goodman, R. Diaz, V.A. Bittner, D.L. Bhatt, M.
357 Szarek, Q.H. Li, G.G. Schwartz, Relation of Red Blood Cell Distribution Width to Risk of
358 Major Adverse Cardiovascular Events, Death, and Effect of Alirocumab After Acute
359 Coronary Syndrome, in: American Heart Association, American Heart Association,
360 Philadelphia, PA, 2019: p. 1.
- 361 [33] J. Lappegård, T. Ellingsen, K. Hindberg, E. Mathiesen, I. Njølstad, T. Wilsgaard, M.-L.
362 Løchen, S. Brækkan, J.-B. Hansen, Impact of Chronic Inflammation, Assessed by hs-CRP, on
363 the Association between Red Cell Distribution Width and Arterial Cardiovascular Disease:
364 The Tromsø Study, *TH Open.* 02 (2018) e182–e189. [https://doi.org/10.1055/s-0038-](https://doi.org/10.1055/s-0038-1651523)
365 [1651523](https://doi.org/10.1055/s-0038-1651523).
- 366 [34] M.A. Zimmerman, Diagnostic Implications of C-Reactive Protein, *Arch Surg.* 138 (2003)
367 220. <https://doi.org/10.1001/archsurg.138.2.220>.
- 368 [35] A. Villaseñor, S.W. Flatt, C. Marinac, L. Natarajan, J.P. Pierce, R.E. Patterson, Postdiagnosis
369 C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study, *Cancer*

- 370 Epidemiol Biomarkers Prev. 23 (2014) 189–199. <https://doi.org/10.1158/1055-9965.EPI->
371 13-0852.
- 372 [36] WHO, C-reactive protein concentrations as a marker of inflammation or infection for
373 interpreting biomarkers of micronutrient status., World Health Organization, Geneva,
374 Switzerland, 2014.
375 http://apps.who.int/iris/bitstream/10665/133708/1/WHO_NMH_NHD_EPG_14.7_eng.pdf
376 ?ua=1.
- 377 [37] M.L. Knight, The Application of High-Sensitivity C-Reactive Protein in Clinical Practice: A
378 2015 Update, *US Pharmacist*. 40 (2015) 50–53.
- 379 [38] S. Jafarnejad, V. Boccardi, B. Hosseini, M. Taghizadeh, Z. Hamedifard, A Meta-analysis of
380 Randomized Control Trials: The Impact of Vitamin C Supplementation on Serum CRP and
381 Serum hs-CRP Concentrations, (2018).
382 <https://doi.org/10.2174/1381612824666181017101810>.
- 383 [39] T.C. Evans, D. Jehle, The red blood cell distribution width, *J. Emerg. Med.* 9 (1991) 71–74.
384 [https://doi.org/10.1016/0736-4679\(91\)90592-4](https://doi.org/10.1016/0736-4679(91)90592-4).
- 385 [40] M.D. Cappellini, I. Motta, Anemia in Clinical Practice—Definition and Classification: Does
386 Hemoglobin Change With Aging?, *Sem. Hematol.* 52 (2015) 261–269.
387 <https://doi.org/10.1053/j.seminhematol.2015.07.006>.
- 388 [41] T.D. Dayspring, S.A. Varvel, L. Ghaedi, D.L. Thiselton, J. Bruton, J.P. McConnell, Biomarkers
389 of cholesterol homeostasis in a clinical laboratory database sample comprising 667,718
390 patients, *Journal of Clinical Lipidology*. 9 (2015) 807–816.
391 <https://doi.org/10.1016/j.jacl.2015.08.003>.

- 392 [42] W.S. Harris, J.V. Pottala, R.S. Vasan, M.G. Larson, S.J. Robins, Changes in erythrocyte
393 membrane trans and marine fatty acids between 1999 and 2006 in older Americans, *J.*
394 *Nutr.* 142 (2012) 1297–1303. <https://doi.org/10.3945/jn.112.158295>.
- 395 [43] T. Nemkov, J.A. Reisz, Y. Xia, J.C. Zimring, A. D’Alessandro, Red blood cells as an organ?
396 How deep omics characterization of the most abundant cell in the human body highlights
397 other systemic metabolic functions beyond oxygen transport, *Expert Review of*
398 *Proteomics.* 15 (2018) 855–864. <https://doi.org/10.1080/14789450.2018.1531710>.
- 399 [44] R. Huisjes, A. Bogdanova, W.W. van Solinge, R.M. Schiffelers, L. Kaestner, R. van Wijk,
400 Squeezing for Life – Properties of Red Blood Cell Deformability, *Front. Physiol.* 9 (2018)
401 656. <https://doi.org/10.3389/fphys.2018.00656>.
- 402 [45] P.L. Else, A.J. Hulbert, Membranes as metabolic pacemakers, *Clin Exp Pharmacol Physiol.*
403 30 (2003) 559–564. <https://doi.org/10.1046/j.1440-1681.2003.03883.x>.
- 404 [46] T.R. Witte, A.J. Salazar, O.F. Ballester, W.E. Hardman, RBC and WBC fatty acid composition
405 following consumption of an omega 3 supplement: Lessons for future clinical trials, *Lipids*
406 *Health Dis.* 9 (2010) 31. <https://doi.org/10.1186/1476-511X-9-31>.
- 407 [47] U. Radzikowska, A.O. Rinaldi, Z. Çelebi Sözen, D. Karaguzel, M. Wojcik, K. Cypryk, M.
408 Akdis, C.A. Akdis, M. Sokolowska, The Influence of Dietary Fatty Acids on Immune
409 Responses, *Nutrients.* 11 (2019) 2990. <https://doi.org/10.3390/nu11122990>.
- 410 [48] T. Kamada, T. Yamashita, Y. Baba, M. Kai, S. Setoyama, Y. Chuman, S. Otsuji, Dietary
411 Sardine Oil Increases Erythrocyte Membrane Fluidity in Diabetic Patients, *Diabetes.* 35
412 (1986) 604–611.

- 413 [49] H.F. Turk, R.S. Chapkin, Membrane lipid raft organization is uniquely modified by n-3
414 polyunsaturated fatty acids, *PLEFA*. 88 (2013) 43–47.
- 415 [50] K. Gawrisch, N.V. Eldho, L.L. Holte, The structure of DHA in phospholipid membranes,
416 *Lipids*. 38 (2003) 445–452.
- 417 [51] E. Tajima, S. Abe, R. Watanabe, Y. Koyabu, F. Saito, H. Kaneda, M. Sakuma, S. Toyoda, T.
418 Inoue, Effects of purified eicosapentaenoic acid on red blood cell distribution width and
419 vascular endothelial function in patients with coronary artery disease, *Vasc Fail*. 1 (2017)
420 15–21. https://doi.org/10.30548/vascfail.1.1_15.
- 421 [52] J. Kim, H. Lee, S. Shin, Advances in the measurement of red blood cell deformability: A
422 brief review, *J. Cell Biotechnol*. 1 (2015) 63–79. <https://doi.org/10.3233/JCB-15007>.
- 423 [53] G.L. Salvagno, F. Sanchis-Gomar, A. Picanza, G. Lippi, Red blood cell distribution width: A
424 simple parameter with multiple clinical applications, *Critical Reviews in Clinical Laboratory*
425 *Sciences*. 52 (2015) 86–105. <https://doi.org/10.3109/10408363.2014.992064>.
- 426 [54] I. Liguori, G. Russo, F. Curcio, G. Bulli, L. Aran, D. Della-Morte, G. Gargiulo, G. Testa, F.
427 Cacciatore, D. Bonaduce, P. Abete, Oxidative stress, aging, and diseases, *Clin. Intervent.*
428 *Aging*. Volume 13 (2018) 757–772. <https://doi.org/10.2147/CIA.S158513>.
- 429 [55] M. Minetti, L. Agati, W. Malorni, The microenvironment can shift erythrocytes from a
430 friendly to a harmful behavior: Pathogenetic implications for vascular diseases,
431 *Cardiovascular Research*. 75 (2007) 21–28.
432 <https://doi.org/10.1016/j.cardiores.2007.03.007>.
- 433 [56] J. Heshmati, M. Morvaridzadeh, S. Maroufizadeh, A. Akbari, M. Yavari, A. Amirinejad, A.
434 Maleki-Hajiagha, M. Sepidarkish, Omega-3 fatty acids supplementation and oxidative

- 435 stress parameters: A systematic review and meta-analysis of clinical trials,
436 Pharmacological Research. 149 (2019) 104462.
437 <https://doi.org/10.1016/j.phrs.2019.104462>.
- 438 [57] S. Ranka, S. Lahan, T. Dalia, A. Tripathi, A. Goyal, J. Sreenivasan, S. Taduru, M. Muhammed,
439 P. Moriarty, Association Between Red Cell Distribution Width and Cardiovascular
440 Outcomes – Systematic Review and Meta-Analysis, MRAJ. 9 (2021).
441 <https://doi.org/10.18103/mra.v9i7.2468>.
- 442 [58] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms
443 and clinical relevance, Bioch. Biophys. Acta: Mol Cell Biol Lipids. 1851 (2015) 469–484.
444 <https://doi.org/10.1016/j.bbalip.2014.08.010>.
- 445 [59] P.C. Calder, Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving
446 mediators: Concentrations in humans and the effects of age, sex, disease and increased
447 omega-3 fatty acid intake, Biochimie. 178 (2020) 105–123.
448 <https://doi.org/10.1016/j.biochi.2020.08.015>.
- 449 [60] J.D. Fontes, F. Rahman, S. Lacey, M.G. Larson, R.S. Vasan, E.J. Benjamin, W.S. Harris, S.J.
450 Robins, Red blood cell fatty acids and biomarkers of inflammation: A cross-sectional study
451 in a community-based cohort, Atherosclerosis. 240 (2015) 431–436.
452 <https://doi.org/10.1016/j.atherosclerosis.2015.03.043>.
- 453 [61] K. Li, T. Huang, J. Zheng, K. Wu, D. Li, Effect of Marine-Derived n-3 Polyunsaturated Fatty
454 Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α : A Meta-Analysis,
455 PLoS ONE. 9 (2014) e88103. <https://doi.org/10.1371/journal.pone.0088103>.

- 456 [62] US Dept Health & Human Services, Nutrient Assessment for DRI Review, Nutrient
457 Assessment for DRI Review. (2014). [https://health.gov/our-work/food-nutrition/dietary-](https://health.gov/our-work/food-nutrition/dietary-reference-intakes-dris/nutrient-assessment-dri-review)
458 [reference-intakes-dris/nutrient-assessment-dri-review](https://health.gov/our-work/food-nutrition/dietary-reference-intakes-dris/nutrient-assessment-dri-review) (accessed October 20, 2020).
- 459 [63] M.I. McBurney, J.B. Blumberg, R.B. Costello, M. Eggersdorfer, J.W.E. Jr, W.S. Harris, E.J.
460 Johnson, S.H. Mitmesser, R.C. Post, D. Rai, L.J. Schurgers, Beyond Nutrient Deficiency—
461 Opportunities to Improve Nutritional Status and Promote Health Modernizing DRIs and
462 Supplementation Recommendations, *Nutrients*. 13 (2021) 1–25.
463 <https://doi.org/10.3390/nu13061844>.
- 464 [64] P.M. Kris-Etherton, J.A. Grieger, T.D. Etherton, Dietary Reference Intakes for DHA and EPA,
465 PLEFA. 81 (2009) 99–104. <https://doi.org/10.1016/j.plefa.2009.05.011>.
- 466 [65] W.S. Harris, D. Mozaffarian, M. Lefevre, C.D. Toner, J. Colombo, S.C. Cunnane, J.M. Holden,
467 D.M. Klurfeld, M.C. Morris, J. Whelan, Towards establishing dietary reference intakes for
468 eicosapentaenoic and docosahexaenoic acids, *J. Nutr.* 139 (2009) 804S-819S.
469 <https://doi.org/10.3945/jn.108.101329>.
- 470 [66] A. Daak, A. Rabinowicz, K. Ghebremeskel, Omega-3 fatty acids are a potential therapy for
471 patients with sickle cell disease, *Nat Rev Dis Primers*. 4 (2018) 15.
472 <https://doi.org/10.1038/s41572-018-0012-9>.
- 473 [67] A.A. Daak, M.A. Lopez-Toledano, M.M. Heeney, Biochemical and therapeutic effects of
474 Omega-3 fatty acids in sickle cell disease, *Complement. Therap. Med.* 52 (2020) 102482.
475 <https://doi.org/10.1016/j.ctim.2020.102482>.
- 476 [68] M. Takahashi, M. Myojo, A. Watanabe, A. Kiyosue, K. Kimura, J. Ando, Y. Hirata, I. Komuro,
477 Effect of purified eicosapentaenoic acid on red cell distribution width in patients with

- 478 ischemic heart disease, *Heart Vessels*. 30 (2015) 587–594.
- 479 <https://doi.org/10.1007/s00380-014-0526-3>.
- 480 [69] L.T. Meital, M.T. Windsor, R.M.L. Ramirez Jewell, P. Young, K. Schulze, R. Magee, J.
- 481 O’Donnell, P. Jha, M. Perissiou, J. Golledge, T.G. Bailey, P. Brooks, C.D. Askew, F.D. Russell,
- 482 n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized
- 483 controlled trial, *J. Lipid Res*. 60 (2019) 1154–1163. <https://doi.org/10.1194/jlr.P093013>.
- 484 [70] E. Wolin, J. White, J.V. Pottala, M. Sasinowski, T. Dall, T.D. Dayspring, J.P. McConnell, D.M.
- 485 Hoefner, S.A. Varvel, D.L. Thiselton, G.R. Warnick, W.S. Harris, Comparison of
- 486 cardiometabolic risk biomarkers from a national clinical laboratory with the US adult
- 487 population, *J. Clin. Lipid*. 9 (2015) 817–823. <https://doi.org/10.1016/j.jacl.2015.07.014>.
- 488 [71] R.A. Murphy, P.P. Devarshi, S. Ekimura, K. Marshall, S. Hazels Mitmesser, Long-chain
- 489 omega-3 fatty acid serum concentrations across life stages in the USA: an analysis of
- 490 NHANES 2011–2012, *BMJ Open*. 11 (2021) e043301. [https://doi.org/10.1136/bmjopen-](https://doi.org/10.1136/bmjopen-2020-043301)
- 491 [2020-043301](https://doi.org/10.1136/bmjopen-2020-043301).
- 492 [72] V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red
- 493 cell distribution width and high sensitivity C-reactive protein for coronary heart disease
- 494 mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES, *Int.*
- 495 *J. Cardiol*. 168 (2013) 5156–5161. <https://doi.org/10.1016/j.ijcard.2013.07.109>.
- 496 [73] N. Shah, M. Pahuja, S. Pant, A. Handa, V. Agarwal, N. Patel, R. Dusaj, Red cell distribution
- 497 width and risk of cardiovascular mortality: Insights from National Health and Nutrition
- 498 Examination Survey (NHANES)-III, *International Journal of Cardiology*. 232 (2017) 105–110.
- 499 <https://doi.org/10.1016/j.ijcard.2017.01.045>.

500 [74] W.S. Harris, The Omega-3 Index: Clinical Utility for Therapeutic Intervention, *Curr Cardiol*
501 Rep. 12 (2010) 503–508. <https://doi.org/10.1007/s11886-010-0141-6>.
502

Table 1. Characteristics of the study population. Mean±SD.				
Variable ¹	All (n=25,485)	Males (n=12,811)	Females (n=12,674)	Male vs Female Adjusted ² p-value
O3I (%)	4.99±1.83	4.90±1.81	5.07±1.85	0.0003
RDW (%)	13.60±0.90	13.60±0.83	13.69±0.96	0.0002
MCV (fL)	92.45±4.27	92.33±4.25	92.57±4.28	0.36
Hb (g/dL)	14.40±1.21	15.14±1.03	13.65±0.88	<0.00001
CRP (mg/L)	1.23±0.77	1.21±0.75	1.25±0.78	<0.00001
BMI (kg/m ²)	27.7±5.3	28.8±4.8	25.6±5.5	<0.00001
Age (years)	54.3±14.8	54.1±14.4	54.4±15.2	0.077
¹ O3I, Omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index. ² Models were adjusted for age, BMI, and CRP (except when the model was predicting these variables).				

503

504

Variable ¹	Female ² (n=12,674)		Male ³ (n=12,811)		Sex*O3I Interaction
	O3I ≤5.6% (n=8,475)	O3I >5.6% (n=4,199)	O3I ≤5.6% (n=9,037)	O3I >5.6% (n=3,774)	Adjusted ⁴ p-value
O3I (%)	3.99±0.86	7.26±1.32	3.94±0.86	7.21±1.33	0.47
RDW	13.64±0.98	13.52±0.90	13.60±0.84	13.59±0.80	0.00066
CRP (mg/L)	1.31±0.79	1.13±0.75	1.26±0.76	1.09±0.71	0.03
BMI (kg/m ²)	27.2±5.7	25.3±4.9	29.1±4.9	28.1±4.5	<0.00001
Age (years)	52.6±15.6	57.9±13.5	52.6±14.6	57.9±13.3	0.90

¹ O3I, omega-3 index; RDW, red blood cell distribution width; MCV, mean corpuscular volume; Hb, hemoglobin; CRP, high-sensitivity C-reactive protein; BMI, body mass index.

² All variables between O3I categories (≤5.6% vs >5.6%) for females were p<0.0001 in both adjusted and unadjusted analyses.

³ All variables between O3I categories (≤5.6% vs >5.6%) for males were p<0.0001 in both adjusted and unadjusted analyses, except for unadjusted difference in RDW by O3I category, p=0.31.

⁴ Model further adjusted for age, BMI, and CRP.

505

506

507 Figure 1. Analytical sample flow chart. RDW, red blood cell distribution width; O3I, omega-3
508 index; MCV, mean corpuscular cell volume; Hb, hemoglobin.

509

510 Figure 2. The unadjusted (A) and adjusted for age, sex, BMI and CRP (B) relationship between
511 the red blood cell distribution width (RDW) and omega-3 index (O3I) in 25,485 adults without
512 inflammation or anemia. (Predicted means and 95% confidence bands).

513

514 Figure 3. The unadjusted (A) and adjusted for age, BMI, and CRP (B) relationships between the
515 red blood distribution width (RDW) and omega-3 index (O3I) in 12,811 males (A) and 12,674
516 females (B) without inflammation or anemia. (Predicted means and 95% confidence bands).





